Jade Biosciences Inc
JBIO
NASDAQ
Biotechnology
$24.71
USD
+0.90 (+3.78%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $1.51B
Volume 1.5M
Revenue
—
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
—
TTM
— YoY
Operating Cash Flow
—
TTM
— YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | — | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | — | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | — | 0.0 | 0.0 |
Selling, General & Administrative | 5.2 | 5.4 | — | 7.4 | 8.9 |
Other Operating Expenses | 0.0 | 0.0 | — | 0.0 | 0.0 |
Total Operating Expenses | 27.8 | 27.4 | — | 43.4 | 58.9 |
Operating Income | -27.8 | -27.4 | — | -43.4 | -58.9 |
EBITDA | -27.8 | -27.4 | — | -43.4 | -58.9 |
Other Income / Expense | -6.2 | -0.0 | — | -0.0 | -0.1 |
Total Other Income / Expense | -4.4 | 2.2 | — | 3.1 | 3.2 |
Income Before Income Taxes | -32.1 | -25.2 | — | -40.4 | -55.8 |
Income Taxes | 0.0 | 0.0 | — | 0.0 | 0.0 |
Net Income | -32.1 | -25.2 | — | -40.4 | -55.8 |
Consolidated Net Income / Loss | -32.1 | -25.2 | — | -40.4 | -55.8 |
Net Income Attributable to Common Shareholders | -24.6 | -19.1 | — | -33.1 | -46.2 |
Basic EPS | -$0.86 | -$0.48 | — | -$0.57 | -$0.76 |
Diluted EPS | -$0.86 | -$0.48 | — | -$0.57 | -$0.76 |
Basic Shares Outstanding | 28.4M | 39.6M | — | 57.8M | 61.1M |
Diluted Shares Outstanding | 28.4M | 39.6M | — | 57.8M | 61.1M |